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We have examined the antithrombin effects of various phosphate-containing polyanions (including linear polyphos- 
phates, polynucleotides and the phosphoserine glycoprotein, phosvitin) on the glycosaminoglycan-binding plasma pro- 
teinase inhibitors, antithrombin III (ATIII) and heparin cofactor II (HCII). These phosphate-containing polyanions ac- 
celerate the HCII-thrombin reaction, as much as 1600-fold in the case of phosvitin. The HCII-thrombin reaction with 
both phosvitin and polynucleotides appears to follow the ternary complex mechanism. The HCII-thrombin complex is 
rapidly formed in the presence of these phosphate polyanions (each at 10 fig/ml) when ‘ZSI-labeled thrombin is incubated 
with human plasma (ex vivo). None of these phosphate polyanions accelerate the ATIII-thrombin reaction. Our results 
suggest hat the antithrombotic effect of these phosphate-containing polyanions is mediated by HCII activation and not 
by ATIII. 
Heparin cofactor II; Antithrombin III; Phosphate polyanion 
1. INTRODUCTION 
Heparin is a glycosaminoglycan that is used 
therapeutically as an anticoagulant [l]. The anti- 
thrombin activity of heparin is effected through in- 
teraction with two plasma glycoproteins, anti- 
thrombin III (ATIII) and heparin cofactor II 
(HCII) (for review see [2-61). AT111 inhibits all of 
the proteinases involved in intrinsic blood coagula- 
tion [6]. The coagulation proteinase sp cificity of 
HCII is limited to thrombin [7]. 
The structure of the heparin (polyanion)-binding 
sites in AT111 and HCII remain to be fully 
elucidated. ‘However, the antithrombin action of 
heparin is attributed in part to its ability to bind 
both inhibitor (ATIII/HCII) and thrombin to 
form a ternary complex ([8-lo] and references 
cited therein). Dermatan sulfate also accelerates 
Correspondence address: F.C. Church, Division of 
Hematology, Campus Box no. 7035, 416 Burnett-Womack 
Bldg, University of North Carolina, Chapel Hill, NC 27599, 
USA 
the HCII-thrombin reaction but it has essentially 
no effect on the ATIII-thrombin reaction [l l-131. 
We studied the interaction of various phosphate- 
containing polyanions with HCII and AT111 to ex- 
amine further the specificity of the heparin (poly- 
anion)-binding sites of these proteinase inhibitors. 
We report here that the antithrombin action of 
various phosphate-containing polyanions (in- 
cluding linear polyphosphates, polynucleotides and 
phosvitin, a phosphoserine glycoprotein) is 
mediated through HCII and not through ATIII. 
The findings further suggest that these phosphate- 
containing polyanions are potential therapeutic an- 
tithrombotics. 
2. EXPERIMENTAL 
2.1. Materials 
HCII, AT111 and thrombin were prepared from human 
plasma as described previously [14,15] and their purity assessed 
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
Linear polyphosphates, polynucleotides, phosvitin, poly- 
(ethyleneglycol) (jk& = 8000), and salmon protamine sulfate 
were obtained from Sigma (St. Louis, MO). Dansyl-Glu-Gly- 
Published by Elsevier Science Publishers B. K (Biomedical Division) 
26 00145793/88/$3.50 0 1988 Federation of European Biochemical Societies 
Volume 237, number 1,2 FEBS LETTERS September 1988 
Arg chloromethylketone (DEGR) was from Calbiochem (La 
Jolla, CA). Activated partial thromboplastin time (aPTT) 
reagents were obtained from Pacific Hemostasis (Ventura, CA). 
‘ZSI-labeled tbrombin (with approx. 3 x 10” dpm/mol pro- 
teinase) was prepared as detailed previously [16]. DEGR- 
thrombin [lo] and lysine-modified HCII [17] were prepared 
essentially as described previously. The IU, values and extinction 
coefficients (ml. mg-’ . cm-’ at 280 nm) were taken as 65600 
and 0.593 for HCII, 56600 and 0.624 for AT111 and 36600 and 
1.75 for thrombin [5]. 
2.2. Assays 
HCII (and ATIII) activity was determined by measuring the 
rate of thrombin inhibition in the absence and presence of either 
heparin or the phosphate-containing polyanions in 50 mM tri- 
ethanolamine-acetate, 100 mM NaCl, 0.1% poly(ethylene- 
glycol) buffer at pH 8.0 and 25°C with at least a lo-fold molar 
excess of proteinase inhibitor to thrombin as described previous- 
ly [5,14,15]. Inhibition rate constants were calculated as detailed 
[16]. The anticoagulant activity of the phosphate-containing 
polyanions was measured using an aPTT clotting assay follow- 
ing the manufacturer’s procedure. 
2.3. Other determinations and methods 
The kinetic model and association rate equations used in this 
study assume that ‘the heparin-catalyzed ATIII- or HCII- 
thrombin reaction is analogous to a bireactant enzyme- 
catalyzed reaction that follows a random order mechanism as 
described previously [8]. PAGE was performed in the Laemmli 
buffer system with 7.5% polyacrylamide gels [18]. Plasma in- 
cubation with 12sI-labeled thrombin was performed essentially 
as described previously [12,16]. Extrinsic fluorescence 
measurements of DEGR-thrombin in the absence and presence 
of various polyanions were performed as described [lo]. 
3. RESULTS 
The effect of linear polyphosphates on thrombin 
inhibition by HCII and AT111 was investigated. 
Tripolyphosphate enhanced the rate of thrombin 
inhibition by HCII, but not by ATIII, in a dose- 
dependent fashion (fig. 1A). The maximal increase 
in activity (-60-fold) was similar when the 
nucleotide analog, ATP, was substituted for tri- 
polyphosphate in the reaction (fig.lA). Larger 
polyphosphate species (with average phosphate 
chain lengths ranging from 4 to 65) also accelerated 
the HCII-thrombin reaction maximally more than 
800-fold but with no effect on the ATIII-thrombin 
reaction (fig.lB). 
In order to examine the influence of the non- 
phosphate components of polyphosphate-contain- 
ing compounds, we compared various polynucleo- 
tides in their ability to augment the rate of the 
HCII-thrombin reaction. The rate of thrombin in- 
hibition by HCII in the presence of synthetic 
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Fig. 1. Thrombin inhibition by HCII (A, A) and AT111 (0, n ) in 
the presence of (A) tripolyphospbate (A, 0) or ATP (A, n ) and 
(B) polyphosphates with average chain lengths ranging from 4 to 
65 (each at 1 mM in phosphate) (A, 0). The inhibition reaction 
was performed as described in section 2. 
Table 1 
Effect of synthetic polynucleotides on the inhibition of 
thrombin by HCII 
Polynucleotidea Rate enhancement (-fold)b 
Poly(guanylate) 400 
Poly(adenylate, guanylate) 430 
Poly(inosinate) 160 
Poly(guanylate, uridylate) 135 
Poly(uridylate) 23 
Poly(adenylate) 21 
Poly(cytidylate) 12 
a With the exception of poly(G) which was 10 pg/ml, the poly- 
nucleotides were 100 pg/ml in the HCII-thrombin reaction as 
detailed in section 2 
b The relative rate of enhancement was compared to the rate 
constant of thrombin inhibition by HCII in the absence of any 
polyanion 
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Fig.2. Apparent second order rate constants (/r~) for thrombin 
inhibition by HCII (A) and AT111 (m) as a function of.phosvitin 
concentration. Inhibition reaction conditions and rate constant 
determinations are detailed in section 2. 
polynucleotides was significantly greater than the 
rate measured in the absence of any polyanion 
(table 1). The maximal effect on HCII-thrombin 
was exhibited by guanylic acid-containing species. 
The polynucleotides did not enhance the ATIII- 
thrombin inhibition rate. 
The ability of phosphate groups to accelerate the 
rate of thrombin inhibition by HCII was further in- 
vestigated with the phosphoserine-containing 
glycoprotein, phosvitin. Fig.2 depicts the concen- 
tration dependence for stimulation of the HCII- 
thrombin reaction rate by phosvitin. The rate con- 
stant for thrombin inhibition by HCII increased 
from 5 x lo4 M-l. min-’ (in the absence of phos- 
vitin) to 8 x lo7 M-’ . min-’ as the phosvitin con- 
centration increased from 0.05 to 30 pg/ml and 
then decreased as phosvitin was increased above 
30 /cg/ml. The relationship between poly-(guanyl- 
ate) (poly(G)) and poly(adenylate, guanylate) con- 
centration and the rate of HCII-thrombin inhibi- 
tion was similar to that of phosvitin (not shown). 
As found for the other phosphate-containing poly- 
anions, phosvitin had no effect on the ATIII- 
thrombin reaction (fig.2). 
The kinetic mechanism of the phosvitin- 
catalyzed HCII-thrombin reaction was evaluated 
by varying the HCII and thrombin concentration 
at a fixed phosvitin concentration (fig.3). Satura- 
tion kinetics were observed with apparent dissocia- 
tion constants for HCII-phosvitin and thrombin- 
phosvitin of 690 and 10 nM, respectively. A similar 
kinetic analysis for the poly(G)-catalyzed HCII- 
-. n -. so -.2s 0 .2s .so .n -10 -5 0 5 10 IS 20 25 
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Fig.3. Kinetics of the phosvitin-HCII-thrombin reaction were analyzed by determining the initial rate (Vi) of thrombin (T) inhibition by 
HCII in the presence of 250 ng/ml phosvitin. (A) Initial T concentration was 5 nM. (B) Initial HCII concentration was 770 nM. Data 
are plotted as described in section 2. 
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thrombin reaction yielded apparent dissociation 
constants for HCII-poly(G) and thrombin-poly(G) 
of 520 and 15 nM, respectively. 
Lysine-modified HCII (phosphopyridoxylated 
to an extent of 4 mol of reagent incorporated/mol 
protein) and DEGR-thrombin were used to assess 
the importance of phosphate-containing polyanion 
binding to both inhibitor and proteinase during 
thrombin inhibition. Modified HCII lost > 80% of 
the heparin (and dermatan sulfate) cofactor activi- 
ty compared to the unmodified proteinase in- 
hibitor. Enhanced thrombin inhibition in the 
presence of phosphate-containing polyanions [for 
instance, poly(G), phosvitin and polyphosphate 
(average chain length of 65)] was greatly reduced 
(an average of 84%) with lysine-modified HCII. 
Poly(G) and polyphosphate (average chain length 
of 65) produced an extrinsic fluorescence signal 
enhancement (- 3-fold) in DEGR-thrombin, in- 
dicating that their binding altered the environment 
of the dansyl moiety in the active site of thrombin. 
Calcium and protamine were added to phosvitin 
and poly(G) to investigate the importance of the 
polyanion charge on the HCII-thrombin reaction. 
The phosvitin-catalyzed HCII-thrombin reaction 
was inhibited more than 97% with rate constants of 
6.6 x lo6 and c 1.6 x lo5 M-‘emin-’ in the 
absence and presence of calcium (10 mM), respec- 
tively. Protamine (at a lOO-fold excess by weight) 
eliminated >98% of the poly(G) effect on the 
HCII-thrombin reaction. 
The anticoagulant activity of phosvitin, poly(G) 
and polyphosphate (average chain lengths of 5 and 
65) was assessed in plasma. In an aPTT clotting 
assay, heparin (by weight) is about 100 times more 
potent as an anticoagulant in plasma than these 
phosphate-containing polyanions. 
The ability of various phosphate-containing 
polyanions to activate HCII was further in- 
vestigated in a plasma system. This ex vivo system 
consisted of incubating 1251-labeled thrombin with 
plasma and then analyzing the reaction products by 
SDS-PAGE and autoradiography. As shown in 
fig.4, incubation of 1251-labeled thrombin with 
plasma either in the presence of phosvitin, poly(G) 
or polyphosphate with a chain length of 65 (each at 
10 pg/ml) was correlated with incorporation into a 
complex with HCII. There was no increase in the 
amount of 1251-labeled thrombin incorporated into 
a complex with AT111 (fig.4). 
Fig.4. Activation of HClI in human plasma was assessed by in- 
cubating ‘251-labeled thrombin (T) (5 nM), for 10 min at 25”C, 
in titrated plasma (diluted 1: 50) in the presence of phosphate- 
containing polyanions (each at lOrg/ml), followed by SDS- 
PAGE and autoradiography as detailed in section 2. T, purified 
ATIII-heparin and HCII-dermatan sulfate complexes with T are 
shown in lanes l-3, respectively; the plasma system with phos- 
vitin, poly(G) and polyphosphate (average chain length of 65) 
are in lanes 4-6, respectively. 
4. DISCUSSION 
In the present study we have shown that various 
phosphate-containing polyanions greatly enhance 
the rate of the HCII-catalyzed thrombin inhibition 
reaction in vitro. Furthermore, the HCII-thrombin 
complex is rapidly formed when “‘I-labeled 
thrombin is incubated with human plasma (ex vivo) 
in the presence of either phosvitin, poly(G) or poly- 
phosphate. In all cases, these phosphate-containing 
polyanions have no effect on the ATIII-catalyzed 
thrombin reaction in vitro or ex vivo. 
HCII is apparently activated by the multiple 
negative charges of these phosphate polyanions, 
since the polyanion effect can be negated by com- 
plexing the phosphate with calcium or protamine. 
The effective phosphate polyanions must also 
possess a specific structure for maximal accelera- 
tion of the HCII-thrombin reaction, as shown by 
the range of rate constants for thrombin inhibition 
by HCII in the presence of various polynucleotides 
(also see [19]). 
The characteristics of the phosvitin- and poly- 
nucleotide-catalyzed HCII-thrombin reaction are 
similar to those found for HCII and thrombin in- 
teractions with heparin or dermatan sulfate 
[8-10,12,17]. The results with chemically modified 
HCII illustrate the importance of phosphate poly- 
anion binding to HCII for the catalytic effect dur- 
ing thrombin inhibition. The results with DEGR- 
thrombin suggest that phosphate polyanion bind- 
ing to the proteinase is important; this effect is 
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similar to that reported for heparin-DEGR- 
thrombin [lo]. The rate constant for phosvitin- 
accelerated thrombin inhibition by HCII increases 
in a concentration-dependent manner, reaches a 
maximum, and then decreases as phosvitin concen- 
tration is further increased. The shape of the curve 
implies that phosvitin (and polynucleotides) forms 
a ternary complex (‘template’) with binding to both 
HCII and thrombin. The binding sites for HCII 
and thrombin probably reside in the phospho- 
serine-rich core region of phosvitin [20]. This is the 
first demonstration that a protein or a poly- 
nucleotide, not a glycosaminoglycan like heparin 
or dermatan sulfate, can serve as a surface (or 
template) for thrombin inhibition by a proteinase 
inhibitor. 
Although an in vivo role can be proposed for 
thrombin inhibition by HCII, the physiological 
function of this inhibitor remains to be fully under- 
stood. Nevertheless, our results support the con- 
cept of a new class of antithrombotics that are 
mediated through HCII and not through ATM. 
The common feature of these compounds is a high 
charge density of phosphate polyanions. Further 
investigation with these antithrombotics may per- 
mit us to evaluate the biological functions of HCII. 
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